Evaluation of Placental Transfusion Techniques in Prevention of Prematurity Related Complications and Effect on Their Hematological Profile
Condition(s) studied
Investigational drug(s) / intervention(s)
intact umbilical milking: Umbilical cord milking will be performed by holding the newborn at or ∼20 cm below the level of the placenta. The cord will be pinched between 2 fingers as close to the placenta as possible and milked toward the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 1- to 2-second pause between each milking motion. This will be repeated for 2-4 times. After completion, the cord will be clamped, and the neonate will be handed to the resuscitation team.
cut umbilical milking: Another technique, used more often in Asia, involves clamping and cutting a long segment of the umbilical cord immediately at birth and passing the baby and the long cord to the pediatric provider, called C-UCM untwists the cord and milks the entire contents into the baby. Milking the cord 2-3 times before clamping may produce a similar placental transfusion as C-UCM
Delayed cord clamping: Infants placed on the maternal abdomen or at the introitus below the level of placenta and waiting at least 30- to 60-second before clamping the cord.
Study summary
The objective of this study is to evaluate the general course and prognosis associated with different methods of placental transfusion (Intact umbilical cord milking, cut- umbilical cord milking and delayed cord clamping) in premature neonates over the first days of life
Eligibility
Primary outcome measure(s)
- Hemoglobin level — on admission (In first day after birth),as well as, at end of first , second and third weeks of lives
hemoglobin level will be measured in gram/dl
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Marwa Mohamed Farag | Alexandria | Egypt | Recruiting |
More Alexandria University trials in Egypt
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06812507 on ClinicalTrials.gov ↗ ← All trials in Egypt